Big tau aggregation disrupts microtubule tyrosination and causes myocardial diastolic dysfunction: from discovery to therapy
Authors:
- Marco LucianiMLMarco Luciani
- Mauro MontalbanoMMMauro Montalbano
- Luca TronconeLTLuca Troncone
- Camilla BacchinCBCamilla Bacchin
- Keita UchidaKUKeita Uchida
- Gianlorenzo DanieleGDGianlorenzo Daniele
- Bethany Jacobs WolfBWBethany Jacobs Wolf
- Helen M ButlerHBHelen M Butler
- Stefano BertoSBStefano Berto
- Cortney GensemerCGCortney Gensemer
- Kelsey MooreKMKelsey Moore
- 1 May 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (17) , 1560-1570
Abstract
Amyloid plaques and neurofibrillary tangles, the molecular lesions that characterize Alzheimer’s disease (AD) and other forms of dementia, are emerging as determinants of proteinopathies ‘beyond the brain’. This study aims to establish tau’s putative pathophysiological mechanistic roles and potential future therapeutic targeting of tau in heart failure (HF). A mouse model of tauopathy and human myocardial and brain tissue from patients with HF, AD, and controls was employed in this study. Tau protein expression was examined together with its distribution, and in vitro tau-related pathophysiological mechanisms were identified using a variety of biochemical, imaging, and functional approaches. A novel tau-targeting immunotherapy was tested to explore tau-targeted therapeutic potential in HF. Tau is expressed in normal and diseased human hearts, in contradistinction to the current oft-cited observation that tau is expressed specifically in the brain. Notably, the main cardiac isoform is high-molecular-weight (HMW) tau (also known as big tau), and hyperphosphorylated tau segregates in aggregates in HF and AD hearts. As previously described for amyloid-beta, the tauopathy phenotype in human myocardium is of diastolic dysfunction. Perturbation in the tubulin code, specifically a loss of tyrosinated microtubules, emerged as a potential mechanism of myocardial tauopathy. Monoclonal anti-tau antibody therapy improved myocardial function and clearance of toxic aggregates in mice, supporting tau as a potential target for novel HF immunotherapy. The study presents new mechanistic evidence and potential treatment for the brain–heart tauopathy axis in myocardial and brain degenerative diseases and ageing. Tangle-like aggregates of hyperphosphorylated tau are present in the heart of patients with dilated cardiomyopathy or Alzheimer’s disease. A mouse model of tauopathy recapitulates the pathological findings of the human disease. Disruption of microtubule de/tyrosination causes myocardial diastolic dysfunction observed in the mouse model, and it can be targeted with immunotherapy. Abbreviations: iDCM, idiopathic dilated cardiomyopathy; PAO, pre-amyloid oligomers; TOMA, tau oligomer monoclonal antibody.Keywords
Funding Information
- American Heart Association (17CSA33620007)
- American Heart Association (20SRG35540029)
- National Institutes of Health (1R01HL156116-01)
- National Institutes of Health (AG054025)
- National Institutes of Health (AG055771)
- Christie Heart and Brain Program and MUSC
- Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch
- Forschungskredit University of Zurich (FK-19-043)
- Società Italiana di Cardiologia
- Merck Sharp and Dohme United Kingdom
- Medical University of South Carolina (5T32 GM132055)
- Alzheimer’s Association Fellowship Program and MUSC
This publication has 40 references indexed in Scilit:
- Cytotoxicity of Intracellular Aβ42Amyloid Oligomers Involves Ca2+Release from the Endoplasmic Reticulum by Stimulated Production of Inositol TrisphosphateJournal of Neuroscience, 2013
- Global Changes in the Rat Heart Proteome Induced by Prolonged Morphine Treatment and WithdrawalPLOS ONE, 2012
- Protein Aggregates and Novel Presenilin Gene Variants in Idiopathic Dilated CardiomyopathyCirculation, 2010
- Transgenic Drosophila models of Alzheimer’s disease and tauopathiesBrain Structure and Function, 2009
- Cerebral hypoperfusion and clinical onset of dementia: The Rotterdam studyAnnals of Neurology, 2005
- Neurovascular regulation in the normal brain and in Alzheimer's diseaseNature Reviews Neuroscience, 2004
- Phosphorylation that Detaches Tau Protein from Microtubules (Ser262, Ser214) Also Protects It against Aggregation into Alzheimer Paired Helical FilamentsBiochemistry, 1999
- The Molecular and Cellular Biology of TauBrain Pathology, 1993
- Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro.Journal of Cell Biology, 1992
- Amyloid β-protein deposition in tissues other than brain in Alzheimer's diseaseNature, 1989